Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Change in Accured Expenses (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Change in Accured Expenses for 11 consecutive years, with $308.2 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 2195.25% to $308.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $311.8 million through Dec 2025, up 2201.11% year-over-year, with the annual reading at $311.8 million for FY2025, 2201.11% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $308.2 million at BeOne Medicines, up from -$72.1 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $308.2 million in Q4 2025, with the low at -$79.3 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $35.6 million, with a median of $1.6 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses crashed 25919.67% in 2022, then skyrocketed 13185.47% in 2023.
  • Over 5 years, Change in Accured Expenses stood at $234.3 million in 2021, then crashed by 100.59% to -$1.4 million in 2022, then surged by 13185.47% to $180.1 million in 2023, then plummeted by 108.17% to -$14.7 million in 2024, then soared by 2195.25% to $308.2 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $308.2 million, -$72.1 million, and $71.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.